首页> 外国专利> Tanshinone ?? inhibiting osteoclast differentiation and bone resorption

Tanshinone ?? inhibiting osteoclast differentiation and bone resorption

机译:丹参酮??抑制破骨细胞分化和骨吸收

摘要

PURPOSE: Tanshinone IIA which is originated from Saliva miltiorrhiza Bunge and has an effect of inhibiting differentiation and bone resorption of an osteoclast is provided. Therefore, the tanshinone IIA is expected to become a material for development of drugs for treating osteosis, rheumatoid arthritis and periodontal disease. CONSTITUTION: The tanshinone II-A is originated from Saliva miltiorrhiza Bunge and represented by the formula 1 which inhibits the differentiation and bone resorption of an osteoclast. An inhibitor of osteoclast differentiation contains the tanshinone II-A as an effective component. The tanshinone II-A inhibits the expression of calcitonin receptors, c-Src and integrin. An inhibitor of bone resorption contains the tanshinone II-A as an effective component. The tanshinone II-A blocks the activity of Akt, ERK and NF-B induced by RANKL by inhibition of the expression of RANKL from the osteoclast precursor.
机译:目的:提供源自丹参唾液的丹参酮IIA,其具有抑制破骨细胞的分化和骨吸收的作用。因此,丹参酮IIA有望成为开发用于治疗骨病,类风湿性关节炎和牙周疾病的药物的材料。组成:丹参酮II-A起源于唾液丹参并由式1表示,其抑制破骨细胞的分化和骨吸收。破骨细胞分化抑制剂包含丹参酮II-A作为有效成分。丹参酮II-A抑制降钙素受体c-Src和整联蛋白的表达。骨吸收抑制剂含有丹参酮II-A作为有效成分。丹参酮II-A通过抑制破骨细胞前体中RANKL的表达来阻断RANKL诱导的Akt,ERK和NF-B的活性。

著录项

  • 公开/公告号KR100517385B1

    专利类型

  • 公开/公告日2005-09-28

    原文格式PDF

  • 申请/专利权人

    申请/专利号KR20030052753

  • 发明设计人 이장희;우은란;

    申请日2003-07-30

  • 分类号A61K31/343;A61P19/10;

  • 国家 KR

  • 入库时间 2022-08-21 22:03:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号